Clinical Trial Update: Prolonged Daily Temozolomide for Low-Grade Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial results from Dana-Farber Cancer Institute evaluate prolonged daily temozolomide in patients with low-grade glioma, including astrocytoma and oligo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Low-grade Glioma
• Oligodendroglioma

Drugs mentioned

• Temodar (Temozolomide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Glioma, Astrocytoma | Phase 2 | Status: COMPLETED